Clamor for GSK Shingles Shot Points to Bigger Profits Clamor for GSK Shingles Shot Points to Bigger Profits

GlaxoSmithKline is facing"unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Business of Medicine News Source Type: news